Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11000 participants.
Also called NCT07181109
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 11,000 participants
- Registry
-
NCT07181109 -
2025-522960-34-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07181109. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-06 (actual); primary completion 2030-09-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Acronym
- ZENITH
- Condition
- High Risk Cardiovascular Disease
- Condition
- Hypertension
- Condition
- High Cardiovascular Risk
- Intervention (Drug)
- Zilebesiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Alnylam Pharmaceuticals
- Collaborator
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct07181109- Content hash
5b758b4ece046b07850dcf9f11d1f07aa5b2d5b3829567f5e9df2f6e87365358